
Opinion|Videos|January 8, 2025
Novel Updates in Second-line Therapies for LR-MDS
Author(s)Guillermo Garcia-Manero, MD, David Swoboda, MD
Panelists discuss real-world evidence on dose escalation of luspatercept in lower-risk myelodysplastic syndrome (LR-MDS) (Patel et al, EHA 2024), highlighting its clinical benefits in improving patient outcomes, and share insights from the MAXILUS trial (Della Porta et al, EHA 2024), considering how this dosing strategy could influence clinical practice and enhance patient care.
Advertisement
Episodes in this series

- Please briefly discuss real-world evidence of dose escalation of luspatercept in LR-MDS (Patel et al, EHA 2024).
- What are the clinical benefits and how can dose escalation in practice improve patient outcomes?
- Please briefly discuss the MAXILUS trial (Della Porta et al, EHA 2024).
- What are your thoughts on this dosing strategy?
- How could this strategy influence care in the clinic?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















